Cargando…

Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials

BACKGROUND: Tasquinimod is an oral quinoline-3-carboxamide derivative for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Tasquinimod has antiangiogenic, immunomodulatory, and antimetastatic properties, but it is also associated with toxicities, including skeletal pain, dig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Ping, Liu, Hongjian, Liu, Xinyu, Zhou, Ge, Liu, Meitian, Yang, Xiaodi, Xiong, Wenjing, Wang, Qi, Ma, Juan, Ren, Zheng, He, Minfu, Zhang, Xiumin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257339/ https://www.ncbi.nlm.nih.gov/pubmed/30431595 http://dx.doi.org/10.1097/MD.0000000000013204

Ejemplares similares

Prognostic value of pretreatment C-reactive protein/albumin ratio in nasopharyngeal carcinoma: A meta-analysis of published literature
por: Yang, Xiaodi, et al.
Publicado: (2018)

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer
por: Gupta, Neha, et al.
Publicado: (2014)

Associations of family relationships and negative life events with depressive symptoms among Chinese adolescents: A cross-sectional study
por: Ren, Zheng, et al.
Publicado: (2019)

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
por: Bratt, O, et al.
Publicado: (2009)

Gender-specific association of metabolic syndrome and its components with arterial stiffness in the general Chinese population
por: Yue, Mengjia, et al.
Publicado: (2017)

Smoking, leisure-time exercise and frequency of self-reported common cold among the general population in northeastern China: a cross-sectional study
por: Zhou, Ge, et al.
Publicado: (2018)

A review of tasquinimod in the treatment of advanced prostate cancer
por: Williamson, Stuart Charles, et al.
Publicado: (2013)

Effects of climate factors on hemorrhagic fever with renal syndrome in Changchun, 2013 to 2017
por: Zhao, Qinglong, et al.
Publicado: (2019)

Mechanisms of action of tasquinimod on the tumour microenvironment
por: Raymond, E., et al.
Publicado: (2013)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

The association between BMI and body weight perception among children and adolescents in Jilin City, China
por: Wang, Yun, et al.
Publicado: (2018)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment
por: Olsson, Anders, et al.
Publicado: (2015)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
por: Sonnenburg, Daniel, et al.
Publicado: (2018)

The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer
por: Papadopoulos, Efthymios, et al.
Publicado: (2023)

Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
por: Zhang, Xuebao, et al.
Publicado: (2019)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

The Associations of Family Functioning, General Well-Being, and Exercise with Mental Health among End-Stage Renal Disease Patients
por: Wang, Qi, et al.
Publicado: (2020)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
por: Nishimoto, Mitsuhisa, et al.
Publicado: (2022)

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
por: Hwang, Clara, et al.
Publicado: (2023)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
por: Olsson, Anders, et al.
Publicado: (2010)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Gender difference in the association of coping styles and social support with psychological distress among patients with end-stage renal disease
por: Wang, Qi, et al.
Publicado: (2020)

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment
por: Isaacs, John T., et al.
Publicado: (2014)

Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
por: Sims, Robert B.
Publicado: (2011)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h91ftrjbk8veatnj9v96t5erje